ZyVersa Therapeutics Inc

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It leverages advanced & proprietary technologies to develop product candidates in the areas of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.

WESTON, Fla., April 25, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of an article in the peer-reviewed Journal of Neuroinflammation supporting the potential of ASC specks as a therapeutic target for Parkinson's disease.

ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson's Disease

WESTON, Fla., April 24, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that internationally recognized authority in the field of innate immunity, Dr. Douglas Golenbock, has joined ZyVersa's Inflammatory Disease Scientific Advisory Board.

ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100

WESTON, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that world renowned inflammasome researchers and inventors of ZyVersa's Inflammasome ASC Inhibitor IC 100 from the University of Miami Miller School of Medicine have published a scientific paper in the peer-reviewed journal, Biomaterials.

ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants

WESTON, Fla., April 13, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of a review article in Frontiers in Pharmacology addressing the NLRP3 inflammasome pathway as a potential drug target for treating mild cognitive impairment (“MCI”) and AD.

ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer's Disease

WESTON, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will appear on Benzinga All Access on April 18, 2023.

ZyVersa Therapeutics' CEO, Stephen C. Glover to Appear on Benzinga 'All Access'

WESTON, Fla., April 11, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will present at Planet MicroCap Showcase 2023 being held in Las Vegas April 25-27.

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Planet MicroCap Showcase

WESTON, Fla., April 10, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that world renowned inflammasome researchers and inventors of ZyVersa's Inflammasome ASC Inhibitor IC 100 have published a scientific paper in the peer-reviewed journal, Brain Pathology. The researchers are from the University of Miami Miller School of Medicine.

ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer's Disease

ZyVersa Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results

ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is taking off on Thursday without any recent news from the biopharmaceutical company. Instead, it looks like investors can thank heavy pre-market trading for the ZVSA stock's rise this morning.

Why Is ZyVersa Therapeutics (ZVSA) Stock Up 35% Today?

WESTON, Fla., March 13, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases with high unmet medical needs, today announced the grant of inducement equity awards to two new employees. The grants were approved by the Compensation Committee of the Board of Directors, effective as of March 8, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).

ZyVersa Therapeutics Reports New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTON, Fla., March 07, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Dr. Richard J. Glassock has joined ZyVersa's Renal Scientific Advisory Board.

ZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board to Support Clinical Advancement of Renal Cholesterol Efflux Mediator™ VAR 200

WESTON, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs, announced today that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President will participate in a fireside chat at the 33rd Annual Oppenheimer Healthcare Conference to be held virtually March 13-15.

ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference

WESTON, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs, announced today that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California.

ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference

WESTON, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of underserved patients with inflammatory and renal diseases, is pleased to announce that world renowned inflammasome researchers from the University of Miami Miller School of Medicine have published a scientific paper in the peer-reviewed journal, Translational Research. The article demonstrates that inflammasome activation and pyroptotic release of active cytokines and ASC specks following TBI is synergistic with inflammasome activation that occurs in AD, heightening the inflammatory response and worsening cognitive outcomes. Furthermore, it shows that IC 100, an inflammasome ASC inhibitor, reduces inflammasome activation that triggers the inflammatory response. Click Here to read the article.

ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer's Disease Following Traumatic Brain Injury

ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is flying higher on Thursday as investors react to a preliminary prospectus for a stock offering. The stock offering announced by ZyVersa Therapeutics covers securities offered by Selling Securityholders.

Why Is ZyVersa Therapeutics (ZVSA) Stock Up 94% Today?

WESTON, Fla., Jan. 27, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases with high unmet medical needs, today announced the grant of an inducement equity award outside ZyVersa's 2022 Equity Incentive Plan to its newly appointed Chief Medical Officer and Senior Vice President of Medical Affairs, Dr. Pablo Guzman. The grants were approved by the Compensation Committee of the Board of Directors, effective as of January 26, 2023, as inducements material to Dr. Guzman entering into employment with ZyVersa in accordance with Nasdaq Listing Rule 5635(c)(4).

ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4)

WESTON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs, announced today that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President will present in person at the BIO CEO & Investor Conference being held February 6-7, 2023 at the Marriot Marquis in New York City.

ZyVersa Therapeutics to Present at BIO CEO & Investor Conference

Live video webcast on Wednesday, January 18th at 2:00 PM ET

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch Event

New appointments bring expertise and proven leadership to ZyVersa to support advancement and development of VAR 200 for renal disease, and IC 100 for inflammatory diseases WESTON, Fla. , Jan. 5, 2023 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa"), a clinical- stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases with high unmet medical needs, announced today the appointments of three new independent board members, bringing the total board membership to seven.

ZyVersa Therapeutics Appoints Three New Board Members

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates to address significant unmet medical needs of patients with inflammatory and renal diseases Lead anti-inflammatory product candidate, inflammasome ASC inhibitor IC 100, blocks initiation and perpetuation of damaging inflammation that is pathogenic in a multitude of inflammatory diseases Lead renal product candidate, phase 2a-ready VAR 200, mediates removal of excess intracellular lipids that contribute to kidney damage leading to end-stage renal disease WESTON, Fla. , Dec. 20, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C.

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 41st Annual J.P.

Larkspur Health Acquisition Corp

ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates for treatment of renal and inflammatory diseases WESTON, Fla. and BRIDGEWATER, N.J.

ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA")

News for ZyVersa Therapeutics Inc Stock (ZVSA)